#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Metastases to peritoneum Hereditary angioedema Metachromatic leukodystrophy Malignant central nervous system neoplasm Alveolar proteinosis Neuropathic arthropathy Ornithine transcarbamoylase deficiency Pancreatic neuroendocrine tumour Lymphoma Marginal zone lymphoma Usher's syndrome Sexually transmitted disease Idiopathic intracranial hypertension Monogenic diabetes Nephroblastoma More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I – Diagnostics Osteosarcoma recurrent – Treatment Methylmalonic acidaemia – Basic Information Glycogen storage disease type II – Basic Information Alport’s syndrome – Basic Information Crigler-Najjar syndrome – Basic Information Atypical haemolytic uraemic syndrome – Basic Information Combined immunodeficiency – Life with Disease Myxofibrosarcoma – Diagnostics Antithrombin III deficiency More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Guselkumab Nefopam Copper (64Cu) Chloride Levoleucovorin Skb264 Bi 1819479 Glutenin Tin816 N-Acetylhistidine Prasinezumab Etranacogene Dezaparvovec Vemurafenib Atorvastatin Lauromacrogol 400 PUCOTENLIMAB Aluminium 13N-AMMONIA [18F]CPFPX Norfloxacin Ampicillin More therapies…

    Learn about Your Condition

    Respiratory distress Systemic candida Trisomy 21 Papilloma viral infection Hot flush Eosinophilic gastritis Alcoholic liver disease Abdominal infection Postoperative delirium Pleural mesothelioma malignant Ocular lymphoma Venous thrombosis Pancreatitis relapsing Vertigo Acarodermatitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Koranyi National Institute For Pulmonology

Koranyi National Institute For Pulmonology

Koranyi Frigyes Ut 1, Budapest, 1121, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Deutivacaftor
    • Vanzacaftor
    • Tezacaftor
    Austria Belgium Czechia Denmark France Germany +10

  • Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Czechia Denmark Estonia France +11

  • Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lurbinectedin
    • Atezolizumab
    Belgium Germany Greece Hungary Italy Poland +1

  • Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Pembrolizumab
    • Vibostolimab
    Hungary Romania

  • Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Adenosquamous cell lung cancer
    • Adenosquamous cell lung cancer recurrent
    • Adenosquamous cell lung cancer stage 0
    Investigated Drugs:
    • D5-Ethyl-Beta-D-Glucuronide
    Czechia Hungary

  • Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    Czechia Estonia France Germany Hungary Italy +6

  • Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Newly Diagnosed Limited-Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Small cell lung cancer limited stage
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Etoposide
    Belgium Bulgaria Estonia France Greece Hungary +5

  • Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Docetaxel
    • SIGVOTATUG VEDOTIN
    Austria Belgium Czechia France Germany Greece +7

  • Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Boserolimab
    • Mk-0482
    • Mk-4830
    Hungary Italy Poland Spain

  • Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Mk-0482
    • Mk-4830
    • Pembrolizumab
    Hungary Italy Poland Spain
Previous Page
1 … 5 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!